Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to compare the difference in change in HbA1c from baseline to treatment endpoint (26 weeks) between 2 mg exenatide once weekly and 1.8 mg once-daily liraglutide in subjects with type 2 diabetes and inadequate glycemic control with lifestyle modification and oral antidiabetic agents (OADs) (metformin, SU, metformin plus an SU, or metformin plus pioglitazone).
Critère d'inclusion
- Type 2 Diabetes